Statistical Analysis of Cost‐effectiveness Data
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; none of the 1 sources its claims cite is checked for support yet.
Abstract
Preface. 1. Concepts. 1.1 Introduction. 1.2 Cost-effectiveness data and the parameters of interest. 1.3 The cost-effectiveness plane, the ICER and INB. 1.4 Outline. 2. Parameter Estimation for Non-censored Data. 2.1 Introduction. 2.2 Cost. 2.3 Effectiveness. 2.4 Summary. 3. Parameter Estimation for Censored Data. 3.1 Introduction. 3.2 Mean Cost. 3.3 Effectiveness. 3.4 Summary. 4. Cost-effectiveness Analysis. 4.1 Introduction. 4.2 Incremental cost-effectiveness ratio. 4.3 Incremental net benefit. 4.4 The cost-effectiveness acceptability curve. 4.5 Using bootstrap methods. 4.6 A Bayesian incremental net benefit approach. 4.7 Kinked thresholds. 4.8 Summary. 5. Cost-effectiveness Analysis: Examples. 5.1 Introduction. 5.2 The CADET-Hp trial. 5.3 Symptomatic hormone-resistant prostate cancer. 5.4 The Canadian implantable defibrillator study (CIDS). 5.5 The EVALUATE trial. 5.6 Bayesian approach applied to the UK PDS study. 5.7 Summary. 6. Power and Sample Size Determination. 6.1 Introduction. 6.2 Approaches based on the cost-effectiveness plane. 6.3 The classical approach based on net benefit. 6.4 Bayesian take on the classical approach. 6.5 The value of information approach. 6.6 Summary. 7. Covariate Adjustment and Sub-group Analysis. 7.1 Introduction. 7.2 Non-censored data. 7.3 Censored data. 7.4 Summary. 8. Multicenter and Multinational Trials. 8.1 Introduction. 8.2 Background to multinational cost-effectiveness. 8.3 Fixed effect approaches. 8.4 Random effects approaches. 8.5 Summary. 9. Modeling Cost-effectiveness. 9.1 Introduction. 9.2 A general framework for modeling cost-effectiveness results. 9.3 Case study: an economic appraisal of the goal study. 9.4 Summary. References. Author Index. Subject Index. Series List.
Overview
CoChat Summary
TL;DR
Willan and Briggs’s book is described as a thorough, authoritative guide to the statistical analysis of cost and effectiveness data collected alongside clinical trials. It covers core estimation, confidence intervals, skewed and censored data, then moves to power/sample size, covariate adjustment, multinational trials, and indirect estimation of ICER.
Key findings
- The book has 9 chapters; the first five are described as the core, giving a self-contained treatment of basic CEA concepts and methods for estimating the mean, variance, and covariance of costs and effectiveness, plus the mean incremental cost-effectiveness ratio (ICER) and mean incremental net benefits (INB) and their confidence intervals.
- The core chapters also address skewed and censored data and include several worked examples illustrating the methods developed.
- The remaining chapters cover more specialized issues including power and sample size determination, using baseline covariates to adjust for confounding, multilevel and multinational trials, and statistical modeling for indirectly estimating ICER.
- The reviewer says the book is “thorough and authoritative,” “well written and very useful,” and an “immensely valuable up-to-date guide” for the literature on CEA data analysis.
Methods
- This is a book review, not an empirical study.
- The text reviewed is a 9-chapter book focused on statistical methods for cost and effectiveness data collected alongside clinical trials.
- The review summarizes the book’s treatment of estimation, confidence intervals, skewed/censored data, power/sample size, covariate adjustment, multinational trials, and indirect ICER estimation.
Limitations
- The authors “could have made their book more readable” and broadened its audience by changing the style of presentation and including other topics.
- The review says the book is not exhaustive for a growing field; it does not cover probabilistic sensitivity analysis of cost-effectiveness models and omits some issues such as specification and measurement errors, heteroscedasticity, and autocorrelation.
- Evident from the review: the treatment is specialized, and the book is aimed mainly at readers with interest or background in CEA/statistics rather than a general audience.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 2 Not valid · 1 Not checked · 6 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These chapters also discuss methods for dealing with such issues as skewed and censored data and provide several examples illustrating the methods developed.”
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Their book is a thorough and authoritative exposition of the subject that can serve as an immensely valuable up-to-date guide to the literature on the statistical analysis of cost and effectiveness data collected alongside clinical trials.”
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The first five chapters, arguably the core of the book, provide a self-contained presentation of the basic concepts of CEA and the statistical methods for estimating key statistics, such as the mean, variance, and covariance of costs and effectiveness, as well as the mean incremental cost-effectiveness ratio (ICER) and the mean incremental net benefits (INB), and their corresponding confidence intervals.”
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nonetheless, the authors could have made their book more readable and garner a larger audience by making some changes to their style of presentation and including other topics.”
In the paper
“Although the book does require prerequisite reading on Bayesian methods (perhaps Gelman, Carlin, Stern, and Rubin 2003), this book should be required reading for all graduate students of statistics, statistical researchers in this field, and students and researchers in other fields that use these technologies.”
What the sources say
- Not checked yetcites Gelman, Carlin, Stern, and Rubin 2003 source
4 more claims
Create a free account to see all 9 claims and to verify the 1 reference still open.
Citations
Cites
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1994) · doi:10.1201/9780429246593 · Cited by 40,500
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Better Bootstrap Confidence Intervals
Efron, B. (1987) · Journal of the American Statistical Association · doi:10.1080/01621459.1987.10478410 · Cited by 3,364 · cited 1×
“Efron and Tibshirani (1993) suggest that the ‘ideal’ bootstrap estimate corresponds to an infinite number of bootstrap re-samples.”
BackgroundSmearing Estimate: A Nonparametric Retransformation Method
Duan, N. (1983) · Journal of the American Statistical Association · doi:10.1080/01621459.1983.10478017 · Cited by 2,232 · cited 1×
“2 A non-parametric ‘smearing’ estimator While the Taylor series approximation may be adequate, there is an alternative approach known as non-parametric smearing that does not require a specific distribution for the error term, see Duan (1983). Note that the expectation of the untransformed cost can be written as a fun…”
BackgroundThe Importance of the Normality Assumption in Large Public Health Data Sets
Lumley, T., Diehr, P., Emerson, S., & Chen, L. (2002) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.23.100901.140546 · Cited by 1,803
Connolly, S. J., Gent, M., Roberts, R. S., Dorian, P., Roy, D., Sheldon, R. S., Mitchell, L. B., Green, M. S., Klein, G. J., & O’Brien, B. (2000) · Circulation · doi:10.1161/01.cir.101.11.1297 · Cited by 1,607 · cited 2×
“The clinical results are reported in Connolly et al. (2000), and the economic evaluation in O’Brien et al. (2000). For this example the measure of effectiveness is survival time, with the duration of interest set to 6.”
BackgroundLaupacis, A., Feeny, D. H., Detsky, A. S., & Tugwell, P. (1992) · Europe PMC (PubMed Central) · Cited by 1,581
Bootstrapping: A Nonparametric Approach to Statistical Inference.
AA, Mooney, C. Z., & Duval, R. D. (1994) · Journal of the American Statistical Association · doi:10.2307/2290969 · Cited by 1,351
Utility approach to measuring health-related quality of life
Torrance, G. W. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90019-1 · Cited by 1,072 · cited 1×
“52 Cost-effectiveness analysis acceptability curve (CEAC) can provide a more flexible and a natural means for expressing the uncertainty of parameter estimators, see van Hout et al. (1994), Briggs and Fenn (1998) and Briggs (1999).”
BackgroundManca, A., Hawkins, N., & Sculpher, M. J. (2005) · Health Economics · doi:10.1002/hec.944 · Cited by 1,024 · cited 1×
“Manca et al. (2005a) discuss the baseline adjustment of QALYs in particular and present simulation results to show that regression adjustment outperforms simple measures of change from baseline, which is sometimes used as a method for adjusting for baseline imbalance in the outcome of interest.”
MethodCost‐effectiveness acceptability curves – facts, fallacies and frequently asked questions
Fenwick, E., O'Brien, B. J., & Briggs, A. (2004) · Health Economics · doi:10.1002/hec.903 · Cited by 943 · cited 1×
“For a more complete discussion on the CEAC and the various shapes that it can take, see Fenwick et al. (2004).”
BackgroundSelf-citationA consumer's guide to subgroup analyses
Oxman, A. D., & Guyatt, G. H. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-1-78 · Cited by 914 · cited 1×
“While analysts should be cautious in their approach to sub-group analysis to avoid the potential pitfalls (Oxman and Guyatt, 1992; Collins et al., 1987) it is often the case that the potential for heterogeneity in cost-effectiveness by patient characteristics is a prime concern of decision makers.”
BackgroundClaxton, K. (1999) · Journal of Health Economics · doi:10.1016/s0167-6296(98)00039-3 · Cited by 889 · cited 1×
“In particular, see Claxton and Posnett (1996) and Willan and Pinto (2005).”
BackgroundHow should cost data in pragmatic randomised trials be analysed?
Thompson, S. G. (2000) · BMJ · doi:10.1136/bmj.320.7243.1197 · Cited by 772
Clarke, P. M., Gray, A. M., Briggs, A., Farmer, A. J., Fenn, P., Stevens, R. J., Matthews, D. R., Stratton, I. M., Holman, R. R., & on behalf of the UK Prospective Diabetes Study (UKPDS) Group (2004) · Diabetologia · doi:10.1007/s00125-004-1527-z · Cited by 615
Self-citationO??Brien, B. J., Drummond, M. F., Labelle, R. J., & William, A. (1994) · Medical Care · doi:10.1097/00005650-199402000-00006 · Cited by 405 · cited 1×
“The concept of WTP is discussed by Pauly (1995), and methods for quantifying it can be found in O’Brien and Gafni (1996), Johnson et al.”
MethodAn economic approach to clinical trial design and research priority-setting
Claxton, K., & Posnett, J. (1996) · Health Economics · doi:10.1002/(sici)1099-1050(199611)5:6<513::aid-hec237>3.0.co;2-9 · Cited by 395
Handling uncertainty when performing economic evaluation of healthcare interventions.
Briggs, & Gray (1999) · Health Technology Assessment · doi:10.3310/hta3020 · Cited by 387
Self-citationWillan, A. R., Briggs, A. H., & Hoch, J. S. (2004) · Health Economics · doi:10.1002/hec.843 · Cited by 364 · cited 8×
“see Willan et al. (2003). Therefore, when the measure of effectiveness is the probability of surviving the duration of interest, e is estimated by”
BackgroundMethodInfluentialSelf-citationESTIMATING CONFIDENCE INTERVALS FOR COST-EFFECTIVENESS RATIOS: AN EXAMPLE FROM A RANDOMIZED TRIAL
CHAUDHARY, M. A., & STEARNS, S. C. (1996) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19960715)15:13<1447::aid-sim267>3.0.co;2-v · Cited by 313
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · Cited by 302
O'Brien, B., & Gafni, A. (1996) · Medical Decision Making · doi:10.1177/0272989x9601600314 · Cited by 294
The black box of health care expenditure growth determinants
Barros, P. P. (1998) · Health Economics · doi:10.1002/(sici)1099-1050(199809)7:6<481::aid-hec353>3.0.co;2-k · Cited by 273
The Distribution of Health Care Costs and Their Statistical Analysis for Economic Evaluation
Briggs, A., & Gray, A. (1998) · Journal of Health Services Research & Policy · doi:10.1177/135581969800300410 · Cited by 272
Self-citationA Randomized Trial of Assertive Community Treatment for Homeless Persons With Severe Mental Illness
Lehman, A. F. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830230076011 · Cited by 263
A Bayesian approach to stochastic cost-effectiveness analysis
Briggs, A. H. (1999) · Health Economics · doi:10.1002/(sici)1099-1050(199905)8:3<257::aid-hec427>3.0.co;2-e · Cited by 253
Self-citationStatistical Issues in Drug Development
Ziegel, E. R., & Senn, S. (1999) · Technometrics · doi:10.2307/1271380 · Cited by 224
Empirical Bayes on vector observations: An extension of Stein's method
EFRON, B., & MORRIS, C. (1972) · Biometrika · doi:10.1093/biomet/59.2.335 · Cited by 224
Collins, R., Gray, R., Godwin, J., & Peto, R. (1987) · Statistics in Medicine · doi:10.1002/sim.4780060308 · Cited by 178 · cited 1×
“While analysts should be cautious in their approach to sub-group analysis to avoid the potential pitfalls (Oxman and Guyatt, 1992; Collins et al., 1987) it is often the case that the potential for heterogeneity in cost-effectiveness by patient characteristics is a prime concern of decision makers.”
BackgroundJonsson, B., Johannesson, M., Kjekshus, J., Olsson, A. G., Pedersen, T. R., Wedel, H., & Scandlnavlan Simvastatin Survival Study Group (1996) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a014994 · Cited by 176
Briggs, A. H., Mooney, C. Z., & Wonderling, D. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19991215)18:23<3245::aid-sim314>3.0.co;2-2 · Cited by 171 · cited 1×
“Bootstrapping has been proposed as another approach for calculating the CEAC and confidence limits for the ICER, see Chaudhary and Sterns (1996), Briggs et al. (1997), Briggs and Fenn (1998), Briggs et al.”
MethodAdequacy of Sample Size in Health Studies.
Ogston, S. A., Lemeshow, S., Hosmer, D. W., Klar, J., & Lwanga, S. K. (1991) · Biometrics · doi:10.2307/2532527 · Cited by 158
Is there a kink in consumers' threshold value for cost‐effectiveness in health care?
O'Brien, B. J., Gertsen, K., Willan, A. R., & Faulkner, A. (2002) · Health Economics · doi:10.1002/hec.655 · Cited by 151
Self-citationCost-effectiveness of assertive community treatment for homeless persons with severe mental illness
Lehman, A. F., Dixon, L., Hoch, J. S., Deforge, B., Kernan, E., & Frank, R. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.174.4.346 · Cited by 126
Manca, A., Rice, N., Sculpher, M. J., & Briggs, A. H. (2005) · Health Economics · doi:10.1002/hec.914 · Cited by 117
Self-citationBayesian Assessment of Sample Size for Clinical Trials of Cost-Effectiveness
O’Hagan, A., & Stevens, J. (2001) · Medical Decision Making · doi:10.1177/02729890122062514 · Cited by 108
Valuing health care benefits in money terms
Pauly, M. V. (1995) · Valuing Health Care · doi:10.1017/cbo9780511625817.006 · Cited by 106
Bayesian Assessment of Sample Size for Clinical Trials of Cost-Effectiveness
O’Hagan, A., & Stevens, J. (2001) · Medical Decision Making · doi:10.1177/0272989x0102100307 · Cited by 102
O'Hagan, A., & Stevens, J. W. (2003) · Health Economics · doi:10.1002/hec.699 · Cited by 101
Parametric modelling of cost data: some simulation evidence
Briggs, A., Nixon, R., Dixon, S., & Thompson, S. (2005) · Health Economics · doi:10.1002/hec.941 · Cited by 100 · cited 4×
“For specific details on the bootstrap estimation of confidence intervals for ICERs, including comparison of the four approaches to interval estimation outlined above, the reader is referred to Briggs et al. (1997) and Briggs et al.”
BackgroundMethodInfluentialSelf-citationPower and Sample Size Calculations for Stochastic Cost-Effectiveness Analysis
Briggs, A. H., & Gray, A. M. (1998) · Medical Decision Making · doi:10.1177/0272989x98018002s10 · Cited by 87
Self-citationBayesian techniques for sample size determination in clinical trials: a short review
Pezeshk, H. (2003) · Statistical Methods in Medical Research · doi:10.1191/0962280203sm345oa · Cited by 84
Cost‐effectiveness of asthma control: an economic appraisal of the GOAL study
Briggs, A. H., Bousquet, J., Wallace, M. V., Busse, W. W., Clark, T. J. H., Pedersen, S., Bateman, E. D., & the GOAL Investigators Group (2006) · Allergy · doi:10.1111/j.1398-9995.2006.01038.x · Cited by 77 · cited 10×
“5 USING BOOTSTRAP METHODS Bootstrapping has been proposed as another approach for calculating the CEAC and confidence limits for the ICER, see Chaudhary and Sterns (1996), Briggs et al. (1997), Briggs and Fenn (1998), Briggs et al.”
BackgroundMethodInfluentialSelf-citationBloomfield, D. J., Krahn, M. D., Neogi, T., Panzarella, T., Smith, T. J., Warde, P. R., Willan, A. R., Ernst, S., Moore, M. J., Neville, A. J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2272 · Cited by 75 · cited 1×
“(1996) and the economics analysis in Bloomfield et al. (1998). Although there was no statistically significant difference in survival, patients experienced a better quality of life with T.”
BackgroundSelf-citationAssessing the appropriateness of combining economic data from multinational clinical trials
Cook, J. R., Drummond, M., Glick, H., & Heyse, J. F. (2003) · Statistics in Medicine · doi:10.1002/sim.1389 · Cited by 75
Hierarchical models for multicentre binary response studies
Skene, A. M., & Wakefield, J. C. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090808 · Cited by 66
The application of REML in clinical trials
Brown, H. K., & Kempton, R. A. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131602 · Cited by 60
Cost-effectiveness analysis for multinational clinical trials
Pinto, E. M., Willan, A. R., & O'Brien, B. J. (2005) · Statistics in Medicine · doi:10.1002/sim.2078 · Cited by 53 · cited 3×
“Formore detail, the reader is referred to Pinto et al. (2005). The shrinkage estimators are based on the assumption that the between-country variation in treatment differences is normally distributed.”
BackgroundInfluentialSelf-citationMcAlister, F. A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.76 · Cited by 53
Incremental net benefit in randomized clinical trials with quality‐adjusted survival
Willan, A. R., Chen, E. B., Cook, R. J., & Lin, D. Y. (2003) · Statistics in Medicine · doi:10.1002/sim.1347 · Cited by 51
Self-citationWillan, A. R. (2004) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200406000-00006 · Cited by 37
Self-citationPower function arguments in support of an alternative approach for analyzing management trials
Willan, A. R. (1994) · Controlled Clinical Trials · doi:10.1016/0197-2456(94)90058-2 · Cited by 12
Self-citationZethraeus, N., & Löthgren, M. (2000) · RePEc: Research Papers in Economics · Cited by 4
Briggs (1998) · doi:10.1002/(sici)1099-1050(199812)7:8
Self-citation
Research works printed but not linked: 3
- Barlow, R., Bartholomew, D., Bremner, J., and Brunk, H. (1972), Statistical Inference Under Order Restrictions , New York: Wiley.
- Robertson, T., Wright, F. T., and Dykstra, R. (1988), Order-Restricted Statistical Inference , New York: Wiley.
- Silvapulle, M., and Sen, P. K. (2004), Constrained Statistical Inference , New York: Wiley.
Cited by
Health-related quality of life measured using the EQ-5D–5L: South Australian population norms
McCaffrey, N., Kaambwa, B., Currow, D. C., & Ratcliffe, J. (2016) · Health and Quality of Life Outcomes · doi:10.1186/s12955-016-0537-0 · Cited by 472
Statistical Issues in Drug Development
Senn, S. (2021) · Wiley eBooks · doi:10.1002/9781119238614 · Cited by 384
A Practical Guide to Value of Information Analysis
Wilson, E. C. F. (2015) · PharmacoEconomics · doi:10.1007/s40273-014-0219-x · Cited by 159
Developing Appropriate Methods for Cost-Effectiveness Analysis of Cluster Randomized Trials
Gomes, M., Ng, E. S.-W., Grieve, R., Nixon, R., Carpenter, J., & Thompson, S. G. (2012) · Medical Decision Making · doi:10.1177/0272989x11418372 · Cited by 151
Hartman, E., Grieve, R., Ramsahai, R., & Sekhon, J. S. (2015) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/rssa.12094 · Cited by 149
“…the relative effectiveness and cost-effectiveness of interventions for target populations that usually differ from those represented by RCT participants (Hoch et al., 2002; Mitra and Indurkhya, 2005; Mojtabai and Zivin, 2003; Nixon and Thompson, 2005; Willan et al., 2004; Willan and Briggs, 2006).”
Background
Metadata
- Authors
- Willan, A. R., & Briggs, A. H.
- Venue
- Wiley eBooks
- Publisher
- Wiley
- Published
- 2006-07-14
- OpenAlex
- W376156748
- Semantic Scholar
- 7d6360d70c621b9a8095d99d2074eceaf1d3839f
- Cited by
- 155
- References
- 53
- Citations by year
- 2021: 11 · 2020: 7 · 2019: 8 · 2018: 6 · 2017: 10 · 2016: 6 · 2015: 8 · 2014: 14 · 2013: 8 · 2012: 16
- FWCI
- 18.19
- Type
- book
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
- Locations
- Wiley eBooks (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Physical Sciences › Mathematics › Statistics and Probability › Advanced Causal Inference Techniques
- Keywords
- cost-effectiveness analysis, incremental cost-effectiveness ratio, incremental net benefit, cost-effectiveness acceptability curves, censored data, bootstrapping, value of information, sample size and power, covariate adjustment, subgroup analysis, random effects models, economic evaluation, health technology assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-24 (prompt extract-v1).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.